《Design and development of 1,3,5-triazine-thiadiazole hybrids as potent adenosine A2A receptor (A2AR) antagonist for benefit in Parkinson’s disease》 was written by Masih, Anup; Singh, Saumya; Agnihotri, Amol Kumar; Giri, Sabeena; Shrivastava, Jitendra Kumar; Pandey, Nidhi; Bhat, Hans Raj; Singh, Udaya Pratap. Recommanded Product: Methyl 4-fluorobenzoateThis research focused ontriazine thiadiazole hybrid antiParkinson neuroprotectant A2AR antagonist Parkinsons disease; 1,3,5-triazine; Adenosine A(2)A receptor; Antagonist; Docking; Parkinson’s disease. The article conveys some information:
Various studies showed adenosine A2A receptors (A2ARs) antagonists have profound therapeutic efficacy in Parkinsons Disease (PD) by improving dopamine transmission, thus being active in reversing motor deficits and extrapyramidal symptoms related to the disease. Therefore, in the presents study, we have showed the development of novel 1,3,5-triazine-thiadiazole derivative as potent A2ARs antagonist. In the radioligand binding assay, these mols. showed excellent binding affinity with A2AR compared to A1R, with significant selectivity. Results suggest, compound 7e as most potent antagonist of A2AR among the tested series. In docking anal. with A2AR protein model, compound 7e found to be deeply buried into the cavity of receptor lined via making numerous interat. contacts with His264, Tyr271, His278, Glu169, Ala63, Val84, Ile274, Met270, Phe169. Collectively, our study demonstrated 1,3,5-triazine-thiadiazole hybrid as a highly effective scaffold for the design of new A2A antagonists.Methyl 4-fluorobenzoate(cas: 403-33-8Recommanded Product: Methyl 4-fluorobenzoate) was used in this study.
Methyl 4-fluorobenzoate(cas: 403-33-8) can be used in the synthesis of trisubstituted imidazole derivatives containing a 4-fluorophenyl group, a pyrimidine ring, and a CN- or CONH2-substituted benzyl moiety.Recommanded Product: Methyl 4-fluorobenzoate
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics